OpenAI launches AI model GPT-Rosalind for life sciences research

OpenAI has unveiled a new artificial intelligence model aimed at advancing biological research and strengthening its presence in the life sciences sector.

The model, called GPT-Rosalind—named after renowned scientist Rosalind Franklin—is built to assist in areas such as biochemistry, drug discovery, and translational medicine.

With increasing demand from pharmaceutical companies, research institutions, and biotech firms for faster and more efficient discovery processes, AI-driven tools are becoming essential in modern scientific workflows.

According to OpenAI, the model is designed to support complex research tasks including synthesizing evidence, generating hypotheses, and planning experiments, ultimately helping researchers speed up early-stage discoveries.

Users can interact with the system to access scientific databases, review recent research papers, utilize specialized tools, and even propose new experimental approaches. The model is developed using OpenAI’s latest internal technologies.

GPT-Rosalind is currently available as a research preview through platforms like ChatGPT, Codex, and API access for selected users. Additionally, OpenAI has introduced a free life sciences plugin for Codex, offering connectivity to more than 50 scientific tools and data sources.

The company is collaborating with major industry players such as Amgen, Moderna, and Thermo Fisher Scientific to integrate the model into real-world research workflows.

In parallel, OpenAI has also released GPT-5.4-Cyber, a specialized version of its flagship model tailored for defensive cybersecurity applications, as competition in advanced AI development intensifies with players like Anthropic introducing new models.

Voice Of Osiz

At Osiz, we see the launch of GPT-Rosalind by OpenAI as a significant leap in applying artificial intelligence to life sciences. This innovation highlights how AI is moving beyond automation into accelerating complex scientific discovery and research workflows. The ability to support hypothesis generation, data analysis, and experimental planning will redefine how pharmaceutical and biotech industries operate. As demand for faster and more accurate research grows, AI-driven models like this will play a crucial role in reducing time-to-market for critical innovations. We believe such advancements will drive a new wave of intelligent healthcare solutions powered by data and automation. At Osiz, we focus on enabling businesses to harness AI for scalable, real-world applications across industries. The future of research lies in AI-powered ecosystems that enhance precision, efficiency, and innovation.

Source: TheHindu.com